Previous 10 | Next 10 |
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BA...
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA...
Context Therapeutics ( NASDAQ: CNTX ), a biotech focused on oncology, shed ~27% pre-market Thursday after announcing preliminary data from an ongoing Phase 2 trial for onapristone extended-release (ONA-XR) oral therapy in metastatic breast cancer. The SMILE study was designed to e...
Data presented at San Antonio Breast Cancer Symposium ® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing Phase 2 endometrial cancer ...
(NewsDirect) Contact Details Proactive Investors USA Proactive Investors USA +1 347-449-0879 na-editorial@proactiveinvestors.com Copyright (c) 2022 TheNewswire - All rights reserved.
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context...
PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone e...
Context Therapeutics press release ( NASDAQ: CNTX ): Q3 GAAP EPS of -$0.24 beats by $0.01 . Cash and cash equivalents of $39 million as of September 30, 2022, expected to provide runway into Q1 2024 . For further details see: Context Therapeutics GAAP EPS...
Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR + recurrent endometrial cancer ONA-X...
Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for breast and gynecologic cancers, today announced the Company will participate in The ThinkEquity Co...
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
Context Therapeutics Inc. Website:
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...